ClinicalTrials.gg
WithdrawnNCT01770223Updated Mar 20, 2017

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

A Phase 4 interventional study of boceprevir and PegIFN-2b in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing boceprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. boceprevir · Hepatitis C.

Enrollment
14th of 15
0 · median 58
Started
2014
the only one that year
Phase 4
3 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
4 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing boceprevir in Hepatitis C, this one is the 14th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 4, and was the 13th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 15 studies testing boceprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About boceprevir

boceprevir: first FDA approval 2011 (VICTRELIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing boceprevir in Hepatitis C as a file.
02

Study summary

This study is being done to find out if participants with insulin resistance and hepatitis C virus genotype 1 (HCV GT1) infections who failed dual therapy with peginterferon alfa (PegIFN) + ribavirin (RBV) will benefit from the addition of boceprevir to PegIFN + RBV (triple therapy).

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Quantifiable serum virus-ribonucleic acid (HCV-RNA)
  • Hepatitis C virus genotype 1
  • Homeostasis Model of Assessment - Insulin Resistance (HOMA IR) > 2.5 in two determinations made 4 weeks apart (the first HOMA evaluation is able to be made 3 weeks before screening visit)
  • Previous failure to achieve SVR with PegIFN plus ribavirin given for a minimum of 12 weeks without dose reduction below 80% of the adequate doses of the two drugs
  • No response, partial response, or relapse after previous therapy
  • Compensated liver disease with or without histologic or non-invasive evidence of liver cirrhosis
  • If heterosexually active, a female participant of and a non-vasectomized male participant who has a female partner of childbearing potential must agree to use 2 effective until 6 months after therapy has ended (7 months for male subject)

Exclusion criteria

Exclusion criteria:

  • Coinfection with genotypes other than HCV-GT1
  • Evidence of decompensated liver disease
  • History of ascites, hepatic encephalopathy or of bleeding varices or severe portal hypertension
  • History or signs or symptoms or evidence of hepatocellular carcinoma (HCC)
  • History of organ transplant
  • Coinfection with virus (HBV) or (HIV)
  • Severe psychiatric disease
  • Inadequately controlled thyroid function
  • Other important comorbidities (cardiovascular diseases, Type 1 diabetes or inadequately controlled type 2 diabetes, , etc)
  • Substances abuse
  • Alcohol intake >20 grams/day for females and >30 grams/day for males
  • History of severe adverse events during previous treatment with PegIFN plus ribavirin including discontinuation of therapy for severe anemia or hematologic toxicity
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Boceprevir + PegIFN-2b + RBV

    All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).

    Drug: boceprevir · Biological: PegIFN-2b · Drug: RBV

Interventions

  • Also known as: SCH 503034

  • BiologicalPegIFN-2b

    Also known as: Peginterferon alfa-2b, PegIntron, SCH 054031

  • DrugRBV

    Also known as: Ribavirin, Rebetol

06

What researchers measure

Primary outcomes

  1. Number of participants with sustained virologic response (SVR) at 24 weeks after the end of 48 weeks of study treatment

    Time frame: Week 72

Secondary outcomes

  1. Change from baseline in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)

    Time frame: Baseline up to 8 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2013
First posted
Jan 17, 2013
Start
Jan 2014
Primary completionEst.
Dec 2015
CompletionEst.
Dec 2015
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01770223
Responsible party
Sponsor
First posted
Jan 17, 2013
Start date
Jan 2014
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Mar 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Boceprevir · Ribavirin

Start the discussion